Senseonics Holdings, Inc.

Senseonics Holdings, Inc. develops and commercializes the Eversense continuous glucose monitoring system for people with diabetes. The company is based in the United States and sells implantable CGM sensors, transmitters, and related components through healthcare and distribution channels in the U.S. and Europe.

−189,5 %

44,7 %

−196,0 %

+56,9 %

4.83

4.55

— Senseonics Holdings, Inc.
%
Implantable CGM systems70% Eversense glucose monitoring systems that measure glucose continuously for diabetes management.
Sensors and consumables20% Disposable sensor components and other recurring consumables used with the system.
Transmitters and hardware7% External transmitter devices and related hardware used to read and transmit glucose data.
Commercial support and services3% Training, patient support, and commercialization-related services tied to adoption and retention.

Senseonics sells primarily to commercial partners, distributors, and healthcare channels that then place Eversense with...

  • Commercial distribution partnersprimary

    Partners that buy Eversense products for resale and commercialization support.

  • Diabetes patientsprimary

    End users of the CGM system who drive recurring sensor consumption and retention.

  • Healthcare providerssecondary

    Clinics and prescribers that recommend, implant, and monitor the system.

  • Payers and reimbursement systemssecondary

    Insurers and coverage decision-makers that determine patient access and adoption.

Senseonics operates in the United States and in markets outside the United States, with revenue disclosed across those...

  • •United States is the core commercial market for Eversense
  • •Outside the United States includes European and other international sales
  • •Revenue depends on diabetes device adoption and reimbursement by market
  • •Commercial operations require local distribution and healthcare channel support

Senseonics’ strategy centers on expanding adoption of Eversense, improving patient access, and strengthening...

01
Grow Eversense adoption and retentionshort-term

Recurring sensor demand depends on keeping patients on the platform.

02
Expand payer coverage and patient accessmedium-term

Reimbursement decisions materially affect device uptake and persistence.

03
Advance next-generation CGM productsmedium-term

Product improvements are needed to compete with larger CGM rivals.

04
Control commercialization more directlyshort-term

Owning more of the sales and distribution process can improve execution.

Senseonics faces concentration risk because a large share of revenue has historically depended on a small number of...

high

Dependence on Ascensia commercialization

A substantial portion of historical revenue came from one commercial partner.

Scope
Sales, distribution, and market access for Eversense
Materiality
high
high

Competitive pressure in CGM

Dexcom, Abbott, and Medtronic have larger scale and broad market presence.

Scope
Pricing, adoption, and share gains in diabetes monitoring
Materiality
high
high

Reimbursement and coverage risk

Patient uptake depends heavily on insurance coverage and payor policy.

Scope
U.S. and international patient access
Materiality
high
medium

Manufacturing and distribution execution

The product requires reliable sterilization, inventory handling, and delivery.

Scope
Sensor availability and product quality
Materiality
medium
medium

Regulatory and product acceptance risk

CGM adoption depends on approvals, certifications, and clinician confidence.

Scope
Launch timing and market expansion
Materiality
medium
Revenue recognition timing
Can shift revenue between periods
Variable consideration
Affects net revenue and contract assets
Contract assets and liabilities
Can materially affect balance sheet presentation
Inventory obsolescence and warranties
Affects cost of sales and operating expenses
Stock-based compensation
Affects operating loss and diluted share metrics

DEXCOM INC

DXCM · Surgical & Medical Instruments & Apparatus

Glucotrack, Inc.

GCTK · Surgical & Medical Instruments & Apparatus

TANDEM DIABETES CARE INC

TNDM · Surgical & Medical Instruments & Apparatus

INSULET CORP

PODD · Surgical & Medical Instruments & Apparatus

Profusa, Inc.

PFSA · Surgical & Medical Instruments & Apparatus

Medtronic plc

MDT · Electromedical & Electrotherapeutic Apparatus

: 29/04/2026